نتایج جستجو برای: hiv fusion inhibitors

تعداد نتایج: 504964  

Journal: :Antimicrobial agents and chemotherapy 2005
Mark A Winters Thomas C Merigan

Treatment of human immunodeficiency virus (HIV) type 1 (HIV-1)-infected individuals with antiretroviral (ARV) drugs is highly effective in inhibiting viral replication, increasing both the duration and the quality of life (71). Regimens consisting of combinations of protease (PR), reverse transcriptase (RT), and fusion inhibitors are the current standard of care and typically reduce the circula...

Journal: :Antimicrobial agents and chemotherapy 2012
Christophe Vanpouille Andrea Lisco Andrea Introini Jean-Charles Grivel Arshi Munawwar Melanie Merbah Raymond F Schinazi Marco Derudas Christopher McGuigan Jan Balzarini Leonid Margolis

Multiple clinical trials have demonstrated that herpes simplex virus 2 (HSV-2) suppressive therapy using acyclovir (ACV) or valacyclovir in HIV-1/HSV-2-infected persons increased the patient's survival and decreased the HIV-1 load. It has been shown that the incorporation of ACV-monophosphate into the nascent DNA chain instead of dGMP results in the termination of viral DNA elongation and direc...

Journal: :Journal of virology 1988
H G Kräusslich H Schneider G Zybarth C A Carter E Wimmer

We expressed the gag and proteinase regions of human immunodeficiency virus (HIV) type 1 by transcription and translation in vitro. A synthetic RNA spanning the gag and pro domains gave primarily the unprocessed capsid precursor pr53. Efficient cleavage of this precursor was observed when the gag and pro domains were placed in the same translational reading frame, yielding equimolar amounts of ...

Journal: :Antimicrobial agents and chemotherapy 2015
Qi Liu Shuai Xia Zhiwu Sun Qian Wang Lanying Du Lu Lu Shibo Jiang

As of 23 July 2014, 837 laboratory-confirmed cases of Middle East respiratory syndrome (MERS-CoV) infection, including 291 deaths, had been reported to the WHO (http://www.who.int /csr/disease/coronavirus_infections/en/), raising concerns about its pandemic potential and calling for the development of vaccines and therapeutics against MERS-CoV infection. We previously identified peptidic HIV-1 ...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 2005
Michael D Miller Romas Geleziunas Elisabetta Bianchi Simon Lennard Renee Hrin Hangchun Zhang Meiqing Lu Zhiqiang An Paolo Ingallinella Marco Finotto Marco Mattu Adam C Finnefrock David Bramhill James Cook Debra M Eckert Richard Hampton Mayuri Patel Stephen Jarantow Joseph Joyce Gennaro Ciliberto Riccardo Cortese Ping Lu William Strohl William Schleif Michael McElhaugh Steven Lane Christopher Lloyd David Lowe Jane Osbourn Tristan Vaughan Emilio Emini Gaetano Barbato Peter S Kim Daria J Hazuda John W Shiver Antonello Pessi

HIV-1 entry into cells is mediated by the envelope glycoprotein receptor-binding (gp120) and membrane fusion-promoting (gp41) subunits. The gp41 heptad repeat 1 (HR1) domain is the molecular target of the fusion-inhibitor drug enfuvirtide (T20). The HR1 sequence is highly conserved and therefore considered an attractive target for vaccine development, but it is unknown whether antibodies can ac...

Alexander Chevalier Alireza Khadem Alla V. Somova Fereidoun Mahboudi Ghader Khalili Igor G. Sidorovich Irina A Nikolaeva, Steven Tugume Buguruca

Background/Objective: Development of a new enzyme-linked immunosorbent assay (ELISA) for screening human blood serum and plasma for antibodies to human immunodeficiency virus type 1 (HIV1) and type 2 (HIV2) as HIV1/2REC ELISA diagnostic kit based on E. coli derived soluble recombinant proteins. Methods: Polypeptides corresponding to HIV1 gp41 and HIV2 gp36 immunodominant regions and HIV1 gag we...

In an attempt to identify potential new agents that are active against HIV-1, a series of novel pyridopyrimidine-5-carbohydrazide derivatives featuring a substituted benzylidene fragment were designed and synthesized based on the general pharmacophore of HIV-1 integrase inhibitors. The cytotoxicity profiles of these compounds showed no significant toxicity to human cells and they exhibited anti...

Journal: :Biochimica et biophysica acta 2001
E De Clercq

Virtually all the compounds that are currently used, or under advanced clinical trial, for the treatment of HIV infections, belong to one of the following classes: (i) nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs): i.e. zidovudine, didanosine, zalcitabine, stavudine, lamivudine, abacavir, emtricitabine, tenofovir (PMPA) disoproxil fumarate; (ii) non-nucleoside reverse transcrip...

Journal: :Topics in HIV medicine : a publication of the International AIDS Society, USA 2004
Robert W Doms

HIV entry to host cells begins with binding of the viral envelope protein to CD4 molecules on the host cell surface. This binding initiates conformational changes in the envelope protein that result in binding to a coreceptor (CCR5 or CXCR4), exposure of a previously hidden domain in the viral protein, insertion of a viral fusion peptide into the host-cell membrane and fusing the viral and cell...

2002

4 Currently available antiretroviral agents exert their anti-HIV effects at 2 postentry stages of viral replication. The nucleoside and nonnucleoside reverse transcriptase inhibitors act to block viral DNA synthesis, whereas the protease inhibitors inhibit a late step in the process of viral budding from the host cell. Viral binding and fusion to the host cell is a multistep process that offers...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید